These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 27853980)

  • 1. Costs of Managing Patients with Diabetes in a Large Health Maintenance Organization in Israel: A Retrospective Cohort Study.
    Porath A; Fund N; Maor Y
    Diabetes Ther; 2017 Feb; 8(1):167-176. PubMed ID: 27853980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs.
    Schwab P; Saundankar V; Bouchard J; Wintfeld N; Suehs B; Moretz C; Allen E; DeLuzio A
    BMJ Open Diabetes Res Care; 2016; 4(1):e000099. PubMed ID: 26925237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain.
    Mata-Cases M; Casajuana M; Franch-Nadal J; Casellas A; Castell C; Vinagre I; Mauricio D; Bolíbar B
    Eur J Health Econ; 2016 Nov; 17(8):1001-1010. PubMed ID: 26542160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.
    Melzer Cohen C; Thorsted BL; Wolden ML; Chodick G; Karasik A
    Diabetes Ther; 2017 Oct; 8(5):1047-1055. PubMed ID: 28884311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of health insurance on direct hospitalisation costs for in-patients with ischaemic stroke in China.
    Yong M; Xianjun X; Jinghu L; Yunyun F
    Aust Health Rev; 2018 Feb; 42(1):39-44. PubMed ID: 28263706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical costs of managed care in patients with type 2 diabetes mellitus.
    Bhattacharyya SK; Else BA
    Clin Ther; 1999 Dec; 21(12):2131-42. PubMed ID: 10645758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The direct medical cost of cardiovascular diseases, hypertension, diabetes, cancer, pregnancy and female infertility in a large HMO in Israel.
    Chodick G; Porath A; Alapi H; Sella T; Flash S; Wood F; Shalev V
    Health Policy; 2010 May; 95(2-3):271-6. PubMed ID: 20061044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
    Ueki K; Sasako T; Okazaki Y; Kato M; Okahata S; Katsuyama H; Haraguchi M; Morita A; Ohashi K; Hara K; Morise A; Izumi K; Ishizuka N; Ohashi Y; Noda M; Kadowaki T;
    Lancet Diabetes Endocrinol; 2017 Dec; 5(12):951-964. PubMed ID: 29079252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major complications have an impact on total annual medical cost of diabetes: results of a database analysis.
    Morsanutto A; Berto P; Lopatriello S; Gelisio R; Voinovich D; Cippo PP; Mantovani LG
    J Diabetes Complications; 2006; 20(3):163-9. PubMed ID: 16632236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
    Li Q; Ganguly R; Ganz ML; Gamble C; Dang-Tan T
    Diabetes Ther; 2018 Jun; 9(3):1279-1293. PubMed ID: 29744818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Quality of Diabetes Care Based Upon Individualised Treatment Goals - A Cross Sectional Study in 4784 Patients in Germany.
    Kloos C; Müller N; Hartmann P; Lehmann T; Sämann A; Roth J; Wolf G; Müller UA
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):294-9. PubMed ID: 26824283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct medical cost and glycemic control in type 2 diabetic Saudi patients.
    Almutairi N; Alkharfy KM
    Appl Health Econ Health Policy; 2013 Dec; 11(6):671-5. PubMed ID: 24174262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost of Managing Type 2 Diabetes Mellitus in Greece: A Retrospective Analysis of 10-Year Patient Level Data "The HERCULES Study".
    Migdalis I; Rombopoulos G; Hatzikou M; Manes C; Kypraios N; Tentolouris N
    Int J Endocrinol; 2015; 2015():520759. PubMed ID: 26089887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The high cost of celiac disease in an Israeli Health Maintenance Organization.
    Heymann AD; Leshno M; Endevelt R; Shamir R
    Health Econ Rev; 2013 Nov; 3(1):23. PubMed ID: 24229448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights for Care: The Healthcare Utilisation and Cost Impact of Managing Type 2 Diabetes-Associated Microvascular Complications.
    Chapman D; Foxcroft R; Dale-Harris L; Ronte H; Bidgoli F; Bellary S
    Diabetes Ther; 2019 Apr; 10(2):575-585. PubMed ID: 30737674
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.